SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

CEL-SCI Reports 73.4% Five-Year Survival With Multikine in Selected Patients

CEL-SCI reported five-year survival of 73.4% among biomarker-selected head and neck cancer patients treated with Multikine.

CVM

Related stories